MoonLake Immunotherapeutics (MLTX) Invested Capital (2020 - 2026)

MoonLake Immunotherapeutics (MLTX) posted quarterly Invested Capital of $15.0 million for Q4 2021.

Analysis

MoonLake Immunotherapeutics (MLTX) Invested Capital (2020 - 2026) Analysis & Trends

MoonLake Immunotherapeutics' Invested Capital history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2021.

In Q4 2021, Invested Capital changed N/A year-over-year to $15.0 million; the TTM figure through Sep 2022 stood at $15.0 million (changed N/A YoY), while the FY2021 annual figure was $15.0 million, changed N/A from the prior year.
Invested Capital for Q4 2021 stood at $15.0 million.
The five-year high for Invested Capital was $15.0 million in Q4 2021, with the low at $15.0 million in Q4 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	MoonLake Immunotherapeutics	1.11 Bn	572.81 Mn	-	527.71 Mn

Historic Data

Download Data